Molecular and immunophenotypic predictors of response to azacitidine (aza) as frontline therapy for acute myeloid leukemia (AML).

被引：0
|
作者：
Zimmerman, Michael Keith Alister
Grunwald, Michael Richard
Symanowski, James Thomas
Gerber, Jonathan Michael
机构：
[1] Levine Canc Inst, Charlotte, NC USA
[2] Levine Canc Inst, Carolinas HealthCare Syst, Charlotte, NC USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2016年 / 34卷 / 15期
关键词：
D O I：
10.1200/JCO.2016.34.15_suppl.7024
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
7024
引用
收藏
页数：4
相关论文
共 50 条
  • [21] Response to Intensive Induction Chemotherapy after Failure of Frontline Azacitidine plus Venetoclax in Acute Myeloid Leukemia
    McMahon, Christine M.
    Gil, Kellen
    Amaya, Maria L.
    Gutman, Jonathan A.
    Hayden, Alexander
    Schwartz, Marc
    Bosma, Grace
    Abbott, Diana
    Stevens, Brett M.
    Smith, Clayton
    Jordan, Craig T.
    Pollyea, Daniel A.
    BLOOD, 2022, 140 : 6185 - 6186
  • [22] Azacitidine in combination with intensive induction chemotherapy in older patients with acute myeloid leukemia: The AML-AZA trial of the study alliance leukemia
    C Müller-Tidow
    P Tschanter
    C Röllig
    C Thiede
    A Koschmieder
    M Stelljes
    S Koschmieder
    M Dugas
    J Gerss
    T Butterfaß-Bahloul
    R Wagner
    M Eveslage
    U Thiem
    S W Krause
    U Kaiser
    V Kunzmann
    B Steffen
    R Noppeney
    W Herr
    C D Baldus
    N Schmitz
    K Götze
    A Reichle
    M Kaufmann
    A Neubauer
    K Schäfer-Eckart
    M Hänel
    R Peceny
    N Frickhofen
    M Kiehl
    A Giagounidis
    M Görner
    R Repp
    H Link
    A Kiani
    R Naumann
    T H Brümmendorf
    H Serve
    G Ehninger
    W E Berdel
    U Krug
    Leukemia, 2016, 30 : 555 - 561
  • [23] Azacitidine in combination with intensive induction chemotherapy in older patients with acute myeloid leukemia: The AML-AZA trial of the study alliance leukemia
    Mueller-Tidow, C.
    Tschanter, P.
    Roellig, C.
    Thiede, C.
    Koschmieder, A.
    Stelljes, M.
    Koschmieder, S.
    Dugas, M.
    Gerss, J.
    Butterfass-Bahloul, T.
    Wagner, R.
    Eveslage, M.
    Thiem, U.
    Krause, S. W.
    Kaiser, U.
    Kunzmann, V.
    Steffen, B.
    Noppeney, R.
    Herr, W.
    Baldus, C. D.
    Schmitz, N.
    Goetze, K.
    Reichle, A.
    Kaufmann, M.
    Neubauer, A.
    Schaefer-Eckart, K.
    Haenel, M.
    Peceny, R.
    Frickhofen, N.
    Kiehl, M.
    Giagounidis, A.
    Goerner, M.
    Repp, R.
    Link, H.
    Kiani, A.
    Naumann, R.
    Bruemmendorf, Th
    Serve, H.
    Ehninger, G.
    Berdel, W. E.
    Krug, U.
    LEUKEMIA, 2016, 30 (03) : 555 - 561
  • [24] Efficacy of the hypomethylating agents as frontline, salvage, or consolidation therapy in adults with acute myeloid leukemia (AML)
    Tawfik, Bernard
    Sliesoraitis, Sarunas
    Lyerly, Susan
    Klepin, Heidi D.
    Lawrence, Julia
    Isom, Scott
    Ellis, Leslie R.
    Manuel, Megan
    Dralle, Sarah
    Berenzon, Dmitriy
    Powell, Bayard L.
    Pardee, Timothy
    ANNALS OF HEMATOLOGY, 2014, 93 (01) : 47 - 55
  • [25] Efficacy of the hypomethylating agents as frontline, salvage, or consolidation therapy in adults with acute myeloid leukemia (AML)
    Bernard Tawfik
    Sarunas Sliesoraitis
    Susan Lyerly
    Heidi D. Klepin
    Julia Lawrence
    Scott Isom
    Leslie R. Ellis
    Megan Manuel
    Sarah Dralle
    Dmitriy Berenzon
    Bayard L. Powell
    Timothy Pardee
    Annals of Hematology, 2014, 93 : 47 - 55
  • [26] Early response to therapy with 5-azacitidine and venetoclax in three transplant-ineligible patients with acute myeloid leukemia (AML)
    Steiner, L.
    Jawhar, M.
    Fabarius, A.
    Nowak, D.
    Hofmann, W. - K.
    Metzgeroth, G.
    ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (SUPPL 2) : 203 - 203
  • [27] HOME AZACITIDINE (AZA) ADMINISTRATION IN MYELODYSPLASTIC SYNDROMES, CMML AND ACUTE MYELOID LEUKEMIA
    Iglesias-Fernandez, M.
    Pereira-Vazquez, M.
    Lopez-Ansoar, E.
    Ulibarrena, C.
    Pardo-Fernandez, M.
    Sastre-Moral, J. L.
    HAEMATOLOGICA, 2012, 97 : 583 - 583
  • [28] Mylotarg in the therapy of acute myeloid leukemia (AML).
    Weber-Nordt, RM
    Lenze, A
    Gottschling, S
    Steiger, S
    Ho, AD
    BLOOD, 2001, 98 (11) : 225B - 225B
  • [29] OVERALL SURVIVAL (OS) AND CLINICAL OUTCOMES IN OLDER PATIENTS WITH ACUTE MYELOID LEUKEMIA (AML) TREATED WITH AZACITIDINE (AZA) OR INTENSIVE CHEMOTHERAPY (IC) IN THE AZA-AML-001 STUDY
    Doehner, H.
    Selleslag, D.
    Cavenagh, J.
    Seymour, J. F.
    Minden, M.
    Recher, C.
    Martinelli, G.
    Mayer, J.
    Font Lopez, P.
    Kim, H. -J.
    Chou, W. -C.
    Kew, A.
    Min, Y. H.
    Songer, S.
    Lucy, L. M.
    Beach, C.
    Dombret, H.
    HAEMATOLOGICA, 2015, 100 : 215 - 216
  • [30] The Safety and Tolerability of Azacitidine (AZA) Are Comparable in Patients with Acute Myeloid Leukemia (AML) or Higher-Risk Myelodysplastic Syndromes (MDS)
    Seymour, John F.
    Silverman, Lewis R.
    Doehner, Hartmut
    Fenaux, Pierre
    Mufti, Ghulam J.
    Santini, Valeria
    Minden, Mark D.
    Stone, Richard M.
    Lucy, Lela M.
    Songer, Stephen
    Dougherty, Donna
    Hinkle, Randy
    Gambini, Dominique
    Beach, C. L.
    Dombret, Herve
    BLOOD, 2015, 126 (23)
12345